Proteases

Pharmacy

Queen's University Belfast

School of Pharmacy

Location
Belfast, United Kingdom
Funding
See university guidance
Application deadline
See university guidance

About the project

The main focus of Dr Burrows’s research team is the identification and characterisation of proteases which potentially represent targets for drug discovery.

One focus is USP17, a deubiquitinase overexpressed in multiple cancers and required for tumour growth and metastases. Dr Burrows has been at the forefront of studies characterising its biological role and assessing its credentials as a therapeutic target.

Another focus is bacterial proteases which contribute to antimicrobial resistance, with the aim of identifying potential antimicrobial targets.

Through his work on proteases, Dr Burrows has also developed an interest in intracellular trafficking, particularly the trafficking of receptors and nanoparticles upon endocytosis.

  • Dr James Burrows: School of Pharmacy

Contact info

  • View Academic Profile
  • j.burrows@qub.ac.uk
  • 02890972703

Research Interests

Open to PhD applications in the field of the biology, characterisation and therapeutic targeting of mammalian and microbial proteases. In particular:

Make a PhD enquiry

  • USP17 as a therapeutic target in cancer
  • Targeting bacterial proteases as an antimicrobial strategy
  • Endocytosis and trafficking of nanoparticles

Public outreach & key achievements

Optimising intracellular delivery of antibiotic loaded PLGA nanoparticles to macrophages (2024) Alsa'd, A. A., Greene, M. K., Tayyem, M., Elmore, B., Abed, A., Burden, R. E., Gilmore, B. F., Scott, C. J. & Burrows, J. F. International Journal of Pharmaceutics. 664, 124567.

USP17 is required for peripheral trafficking of lysosomes (2022) Lin, J., McCann, A., Sereesongsaeng, N., Burden, J., Alsa'd, A. A. M., Burden, R., Micu, I., Williams, R., Van Schaeybroeck, S., Evergren, E., Mullan, P., Scott, C. & Burrows, J., EMBO Reports. e51932.

USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells (2018) McCann, A. P., Smyth, P., Cogo, F., McDaid, W. J., Jiang, L., Lin, J., Evergren, E., Burden, R. E., Van Schaeybroeck, S., Scott, C. J. & Burrows, J. F. Cell communication and signaling. 16, 77.

Research students

PhD Title | Identifying drug targets to combat Acinetobacter baumannii infections.

Name | Bronagh Elmore

Country | United Kingdom

Years of Study | 2019 - 2025

PhD Title | Identifying Protease Drug Targets to Combat ESKAPE Pathogen Infections

Name | Nezar Faya Al Faya

Country | Saudi Arabia

Years of Study | 2022 - 2025

PhD Title | Design, synthesis and assessment of CDK inhibitors

Name | Mashael Alanazi

Country | Saudi Arabia

Years of Study | 2023 - 2026

Alumni: Where are they now

PhD Title | Therapeutic evaluation of an immunomodulatory nanoparticle in Acute Respiratory Distress Syndrome

Name | Dr Michelle Greene

Years of Study | 2011 - 2015

Country | United Kingdom

Current Position | Senior Postdoctoral Fellow, Future Medicines Institute, Queen’s University Belfast, UK

PhD Title | Manipulating PLGA nanoparticle cellular uptake and trafficking

Name | Dr Alhareth Alsa’d

Years of Study | 2019 - 2022

Country | Jordan

Current Position | Assistant Professor, Biopharmaceutics and Clinical Pharmacy Department, Al-Ahliyya Amman University, Jordan

PhD Title | The role of deubiquitinating enzyme USP17 in Non-Small Cell Lung Cancer as a potential therapeutic target.

Name | Dr Jonathan Burden

Years of Study | 2020 - 2024

Country | United Kingdom

Current Position | Postdoctoral Fellow, Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, London, UK

Discover More

  • Faculty of Medicine, Health & Life Sciences
  • School of Pharmacy
  • Materials and Advanced Technologies for Healthcare
  • Future Medicines Institute

Research areas

ProteasesAntimicrobial resistanceAntimicrobial ResistanceNanoparticlesCancer

Related PhD opportunities